Elite Pharmaceuticals, Inc.
ELTP · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $464,706 | $155,363 | $29,374 | $35,321 |
| - Cash | $11,315 | $7,106 | $7,832 | $8,535 |
| + Debt | $10,915 | $11,738 | $3,887 | $2,782 |
| Enterprise Value | $464,306 | $159,994 | $25,429 | $29,567 |
| Revenue | $84,044 | $56,625 | $34,155,114 | $32,262 |
| % Growth | 48.4% | -99.8% | 105,767.6% | – |
| Gross Profit | $40,087 | $26,357 | $16,594,021 | $14,795 |
| % Margin | 47.7% | 46.5% | 48.6% | 45.9% |
| EBITDA | $2,843 | $2,523 | $6,429 | $6,491 |
| % Margin | 3.4% | 4.5% | 0% | 20.1% |
| Net Income | -$4,315 | $20,109 | $4,409,902 | $8,898 |
| % Margin | -5.1% | 35.5% | 12.9% | 27.6% |
| EPS Diluted | -0.004 | 0.02 | 4.35 | 0.007 |
| % Growth | -120.3% | -99.5% | 58,683.8% | – |
| Operating Cash Flow | $7,456 | -$3,282 | $3,339 | $6,508 |
| Capital Expenditures | -$2,525 | -$810 | -$5,737 | -$499 |
| Free Cash Flow | $4,931 | -$4,091 | -$2,398 | $6,010 |